Vaxine

Vaxine is an Australian biotechnology company that develops human and animal vaccines using its proprietary adjuvant. It was established in 2002 by Nikolai Petrovsky. Vaxine is headquartered in Adelaide, Australia.

Vaxine's main product is its polysaccharide-based vaccine adjuvant called Advax. The adjuvant is utilized as a foundation to develop human and animal vaccines. For humans, Vaxine's vaccines that have passed phase III clinical trials are hepatitis B (prophylactic and therapeutic), influenza (seasonal and pandemic), and insect sting allergy. Vaxine is also researching vaccines for diseases such as HIV, ebola, tuberculosis, and most recently, COVID-19.

Vaxine's COVID-19 vaccine is based on the company's previous research on MERS and SARS vaccines. The company is using a recombinant protein-based platform for COVID-19's vaccine. It has announced that it will be conducting phase I clinical trial on human subjects in early July 2020.